BioRay Pharmaceuticals
Shanghai · Founded 2019
About BioRay Pharmaceuticals
BioRay is a commercial-stage biopharmaceutical company with a full suite of end-to-end capabilities in China. We focus on discovering, developing, manufacturing and commercializing medicines for immune-mediated diseases. Leveraging our expertise in immunology and diverse portfolio covering different therapeutic targets and cellular pathways, we are committed to delivering life-changing medicines and other treatment solutions for patients living with autoimmune diseases and cancer. BioRay has full-spectrum R&D expertise from drug discovery to late-stage development, industry-leading commercial-scale manufacturing and quality management systems, and a robust pipeline with more than 20 preclinical candidates and over 10 ongoing clinical projects. In addition, our well-established nationwide commercial operations support three marketed products in mainland China. Currently, we operate four R&D and manufacturing centers in Taizhou, Hangzhou and Shanghai, China and San Diego, US, and have over 1,400 employees worldwide dedicated to building a pre-eminent biopharmaceutical company by offering medicines of the highest quality while pushing the boundaries of scientific discovery. For more information about BioRay, please visit the company website: www.bioraypharm.com
Company Facts
- Founded: 2019
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1,001 – 5,000
- Estimated revenue: $100K – $500K
- Total funding: $357.7M
- Funding stage: Private Equity
- Last round: Private Equity (Jan 2023)
- Website: bioraypharm.comen
- Phone: 086-576-89007929
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/bioray-pharmaceuticals-82578 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.